Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple

Translated title of the contribution: Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis

Inmaculada Tasset, Eduardo Agüera, Félix Gascón, Ana I. Giraldo, Manuel Salcedo, Antonio H. Cruz, Fernando Sánchez, Isaac Túnez

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Introduction. The sensitivity of the central nervous system to oxidative damage and its relationship with inflammatory response are well known. Recent studies have shown that oxidative stress is present in the establishment and development of multiple sclerosis (MS). One of the most recent treatments in this process is natalizumab, a monoclonal antibody. Aim. To evaluate whether the therapeutic effect of natalizumab is associated with the severity of the disease and the oxidative damage. Patients and methods. Researchers recruited twenty patients with relapsing-remitting MS (RRMS) undergoing therapy with natalizumab and distributed, according to the Expanded Disability Status Scale (EDSS), in two groups: RRMS-1 (EDSS < 5) and RRMS-2 (EDSS ≥ 5). Blood samples were taken for an oxidative profile study. Results. Data showed a decrease in carbonylated proteins following treatment with natalizumab. The reduction in oxidative damage rated as protein oxidation is significant between the previous (baseline) situation of the patient and after 14 months' treatment. The most significant decrease coincided with the patients with the highest levels of severity in the process. Although it has not been possible to establish a correlation, the statistical significance is higher for patients in the RRMS-2 group treated with natalizumab. The antioxidant systems, on the other hand, did not display any statistically significant changes. Conclusions. Natalizumab brings about a reduction in carbonylated protein levels.

Translated title of the contributionNatalizumab and reduction of carbonylated proteins in patients with multiple sclerosis
Original languageSpanish
Pages (from-to)449-452
Number of pages4
JournalRevista de neurologia
Volume54
Issue number8
DOIs
StatePublished - Jan 1 2012

Keywords

  • Antioxidant system
  • Carbonylated proteins
  • Multiple sclerosis
  • Natalizumab
  • Oxidative stress
  • Peripheral bio-markers

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Tasset, I., Agüera, E., Gascón, F., Giraldo, A. I., Salcedo, M., Cruz, A. H., Sánchez, F., & Túnez, I. (2012). Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple. Revista de neurologia, 54(8), 449-452. https://doi.org/10.33588/rn.5408.2011672